The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Castration-Resistant Prostate Cancer: AUA Guideline
Abstract
PURPOSE: This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data. MATERIALS AND METHODS: A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate cancer and castration resistance. The search strategy was developed and executed by reference librarians and methodologists to create an evidence report limited to English-language, published peer-reviewed literature. This review yielded 303 articles published from 1996 through 2013 that were used to form a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. RESULTS: Guideline statements were created to inform clinicians on the appropriate use of observation, androgen-deprivation and antiandrogen therapy, androgen synthesis inhibitors, immunotherapy, radionuclide therapy, systemic chemotherapy, palliative care and bone health. These were based on six index patients developed to represent the most common scenarios encountered in clinical practice. CONCLUSIONS: As a direct result of the significant increase in FDA-approved therapeutic agents for use in patients with metastatic CRPC, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. In all cases, patients' preferences and personal goals should be considered when choosing management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Sipuleucel-T immunotherapy is an FDA-approved agent in this setting based upon the results of the IMPACT trial.(19) In this randomized double-blind placebo controlled clinical trial, men with asymptomatic or minimally symptomatic mCRPC and good functional status treated with sipuleucel-T, as compared to placebo, had a…”
BackgroundMethodInfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
The Delphi Technique: Making Sense of Consensus
Hsu, C.-C., & Sandford, B. A. (2007) · University of Massachusetts Amherst · doi:10.7275/pdz9-th90 · Cited by 4,500
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“8 months, OS and PFS favored the abiraterone prednisone cohort.(25) As previously noted, abiraterone prednisone was well tolerated during clinical trial but did show an increase in adverse events, specifically those side effects related to mineralocorticoid excess.”
BackgroundPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationFizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Fracture Prevention With Vitamin D Supplementation: A Meta-analysis of Randomized Controlled Trials
Bischoff-Ferrari, H. A., Willett, W. C., Wong, J. B., Giovannucci, E., Dietrich, T., & Dawson-Hughes, B. (2005) · JAMA · doi:10.1001/jama.293.18.2257 · Cited by 1,530
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
TNM classification of malignant tumors, fifth edition (1997)
Sobin, L. H., & Fleming, I. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971101)80:9<1755::aid-cncr9>3.0.co;2-d · Cited by 1,031
Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Small, E. J., Halabi, S., Dawson, N. A., Stadler, W. M., Rini, B. I., Picus, J., Gable, P., Torti, F. M., Kaplan, E., & Vogelzang, N. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.037 · Cited by 504
Serafini, A. N., Houston, S. J., Resche, I., Quick, D. P., Grund, F. M., Ell, P. J., Bertrand, A., Ahmann, F. R., Orihuela, E., Reid, R. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1574 · Cited by 436
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
Finlay, I. G., Mason, M. D., & Shelley, M. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70206-0 · Cited by 369
Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6908 · Cited by 366
Sartor, O., Reid, R. H., Hoskin, P. J., Quick, D. P., Ell, P. J., Coleman, R. E., Kotler, J. A., Freeman, L. M., & Olivier, P. (2004) · Urology · doi:10.1016/j.urology.2004.01.034 · Cited by 365
THE DELPHI TECHNIQUE: MAKING SENSE OF CONSENSUS PRACTICAL ASSESSMENT
Hsu, C.-T., & Sandford, B. A. (2007) · Cited by 318
Li, K., Kaaks, R., Linseisen, J., & Rohrmann, S. (2012) · Heart · doi:10.1136/heartjnl-2011-301345 · Cited by 314
Lewington, V. J., McEwan, A. J., Ackery, D. M., Bayly, R. J., Keeling, D. H., Macleod, P. M., Porter, A. T., & Zivanovic, M. A. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90257-e · Cited by 279
Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
Pandit-Taskar, N. D., Batraki, M., & Divgi, C. R. (2004) · PubMed · Cited by 224
Strontium-89 chloride for pain palliation in prostatic skeletal malignancy
Laing, A. H., Ackery, D. M., Bayly, R. J., Buchanan, R. B., Lewington, V. J., McEwan, A. J. B., Macleod, P. M., & Zivanovic, M. A. (1991) · The British Journal of Radiology · doi:10.1259/0007-1285-64-765-816 · Cited by 214
Small, E. J., Baron, A. D., Fippin, L., & Apodaca, D. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64924-3 · Cited by 204
Fizazi, K., Beuzeboc, P., Lumbroso, J., Haddad, V., Massard, C., Gross-Goupil, M., Di Palma, M., Escudier, B., Theodore, C., Loriot, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9811 · Cited by 173
Mohler, J. L., Titus, M. A., Bai, S., Kennerley, B. J., Lih, F. B., Tomer, K. B., & Wilson, E. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1343 · Cited by 162
Lind, L., Skarfors, E., Berglund, L., Lithell, H., & Ljunghall, S. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00104-2 · Cited by 153
Antiandrogen withdrawal in castrate‐refractory prostate cancer
Sartor, O. A., Tangen, C. M., Hussain, M., Eisenberger, M. A., Parab, M., Fontana, J. A., Chapman, R., Mills, G. M., Raghavan, D., & Crawford, E. D. (2008) · Cancer · doi:10.1002/cncr.23473 · Cited by 142
Self-citationSartor, O. A., Reid, R. H., Bushnell, D. L., Quick, D. P., & Ell, P. J. (2006) · Cancer · doi:10.1002/cncr.22431 · Cited by 123
Harris, K. A., WEINBERG, V. K., Bok, R., Derynck, M. K., & Small, E. J. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64675-7 · Cited by 117
Intermittent chemotherapy in patients with metastatic androgen‐independent prostate cancer
Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Chi, K. N., Young, J. A., & Henner, W. D. (2007) · Cancer · doi:10.1002/cncr.23163 · Cited by 95
Taplin, M., Regan, M. M., Ko, Y., Bubley, G. J., Duggan, S., Werner, L. L., Beer, T. M., Ryan, C. W., Mathew, P. F., Tu, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1722 · Cited by 86
Self-citationAlternative Antiandrogens to Treat Prostate Cancer Relapse After Initial Hormone Therapy
Kojima, S., Suzuki, H., Akakura, K., Shimbo, M., Ichikawa, T., & Itô, H. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000106190.32540.6c · Cited by 82
Datta, M., & Schwartz, G. G. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0051 · Cited by 72
Andriole, G. L. (2012) · Yearbook of Urology · doi:10.1016/j.yuro.2012.06.017 · Cited by 72
Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease.
Sartor, O. A. (2004) · PubMed · Cited by 70
Oliver, R. T. D., Williams, G., PARIS, A. M. I., & Blandy, J. (1997) · Urology · doi:10.1016/s0090-4295(96)00373-1 · Cited by 67
Miyake, H., Hara, I., & Eto, H. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05766.x · Cited by 61
Keizman, D., Huang, P., Carducci, M. A., & Eisenberger, M. A. (2011) · The Prostate · doi:10.1002/pros.21447 · Cited by 54
Faraday, M. M., Hubbard, H. B., Kosiak, B., & Dmochowski, R. R. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08729.x · Cited by 49
An Evaluation of Intermediate-Dose Ketoconazole in Hormone Refractory Prostate Cancer
Wilkinson, S., & Chodak, G. W. (2004) · European Urology · doi:10.1016/j.eururo.2003.11.031 · Cited by 48
Scholz, M. C., Jennrich, R. I., Strum, S. B., Brosman, S. A., Johnson, H. J., & Lam, R. Y. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000158449.83022.40 · Cited by 48
Doležal, J., Vizda, J., & Odrážka, K. (2006) · Urologia Internationalis · doi:10.1159/000096935 · Cited by 42
Nakabayashi, M., Xie, W., Regan, M. M., Jackman, D. M., Kantoff, P. W., & Oh, W. K. (2006) · Cancer · doi:10.1002/cncr.22085 · Cited by 42
Self-citationLee, C. K. K., Aeppli, D. M., Unger, J., Boudreau, R. J., & Levitt, S. H. (1996) · American Journal of Clinical Oncology · doi:10.1097/00000421-199604000-00003 · Cited by 40
Immunotherapy for Castration-Resistant Prostate Cancer
Sonpavde, G., & Kantoff, P. W. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.07.004 · Cited by 40
Prostate cancer: palliative care and pain relief
Thompson, J. C., Wood, J., & Feuer, D. J. (2007) · British Medical Bulletin · doi:10.1093/bmb/ldm018 · Cited by 38
Nishimura, K., Arichi, N., Tokugawa, S., Yoshioka, I., Kishikawa, H., & Ichikawa, Y. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01681.x · Cited by 31
Ryan, C. J., WEINBERG, V. K., Rosenberg, J. E., Fong, L. H., Lin, A., Kim, J., & Small, E. J. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.011 · Cited by 25
Fujikawa, K., Matsui, Y., Fukuzawa, S., & Takeuchi, H. (2000) · European Urology · doi:10.1159/000020121 · Cited by 22
Integration of Palliative Medicine Into Routine Oncological Care: What Does the Evidence Show Us?
Debono, D. J. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000351 · Cited by 17
Hormonal Sensitivity following Endocrine Withdrawal in Hormone-Refractory Prostate Cancer
Nishiyama, T., & Terunuma, M. (2000) · Urologia Internationalis · doi:10.1159/000064830 · Cited by 7
Integration of Palliative Medicine Into Routine Oncological Care: What Does the Evidence Show Us?
Stone, S. C. (2011) · Cited by 2
Cited by
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., De Bono, J. S., Gale, J., Hetherington, J., Hoskin, P. J., Jones, R. J., Laing, R., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.032 · Cited by 425
Hoskin, P., Sartor, O., O'Sullivan, J. M., Johannessen, D. C., Helle, S. I., Logue, J., Bottomley, D., Nilsson, S., Vogelzang, N. J., Fang, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70474-7 · Cited by 407
Padhani, A. R., Lecouvet, F. E., Tunariu, N., Koh, D.-M., De Keyzer, F., Collins, D. J., Sala, E., Schlemmer, H. P., Petralia, G., Vargas, H. A., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.05.033 · Cited by 333
Metadata
- Authors
- Cookson, M. S., Roth, B. J., Dahm, P., Engstrom, C., Freedland, S. J., Hussain, M., Lin, D. W., Lowrance, W. T., Murad, M. H., Oh, W. K., Penson, D. F., & Kibel, A. S.
- Venue
- Journal of Urology
- Published
- 2013-08
- Volume
- 190
- Issue
- 2
- Pages
- 429-438
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2065142831
- Cited by
- 275
- References
- 67
- FWCI
- 33.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.